Welcome to our dedicated page for Medtronic plc SEC filings (Ticker: MDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Medtronic plc filings document material events, capital structure, registered securities, governance matters, and operating and financial disclosures for a medical-device company organized in Ireland. The 8-K record identifies MDT ordinary shares and multiple series of senior notes listed on the New York Stock Exchange, alongside current reports used for company events and financial-result communications.
The filing record also includes exchange and registration status for debt securities, including a Form 25 notice tied to removal from listing and registration of a guarantor class of senior notes. These disclosures frame Medtronic's public-company obligations around equity, debt instruments, material agreements, and regulatory or clinical developments.
Medtronic plc executive Michael Marinaro, EVP and President of MedSurg and Americas, reported the settlement of performance-based equity awards rather than an open-market trade. On May 26, 2026, he acquired 18,994 Ordinary Shares in connection with the exercise or conversion of derivative awards. These shares were issued upon settlement of performance-vesting share units that were granted on July 31, 2023, with performance certified on May 26, 2026, and that vested on April 24, 2026. Following these transactions, he directly owns 70,593 Medtronic shares.
Medtronic plc executive Harry "Skip" Kiil increased his direct Medtronic shareholding through equity compensation. On May 26, 2026, he acquired 15,195 Ordinary Shares, representing shares issued upon settlement of previously granted performance-vesting share units. These awards were granted on July 31, 2023, vested on April 24, 2026, and were settled after performance was certified on May 26, 2026. Following the transaction, Kiil directly holds 48,233 Ordinary Shares, reflecting compensation-based share delivery rather than an open-market purchase or sale.
Medtronic plc Chief Accounting Officer Denise L. Blomquist reported compensation-related share activity. On May 26, 2026, she acquired 1,712 Ordinary Shares through the exercise or settlement of derivative awards. A related Performance Share Unit award covering 1,621 units converted into Ordinary Shares, leaving no remaining units from that grant. Following these transactions, she directly holds 14,974 Ordinary Shares. Footnotes state that 1,027 of the shares issued from the performance-vesting units will be delivered when her employment with Medtronic ends, underscoring that this is a structured equity award rather than an open-market trade.
Medtronic plc reported a leadership change in its Neuroscience Portfolio. Brett Wall will depart his role as Executive Vice President and President, Neuroscience Portfolio, and remain with the company until September 1, 2026 to support an orderly transition. Dr. Kweli Thompson, currently Senior Vice President and President, Cardiac Rhythm Management, will become Executive Vice President and President, Neuroscience Portfolio effective June 1, 2026. Mr. Wall will receive severance payments and benefits consistent with Medtronic’s standard executive officer severance practices described in its 2025 proxy statement.
Medtronic plc SVP and Chief HR Officer Walter Matthew R. reported a small, routine tax-related share disposition. On the vesting of previously granted restricted stock units, 35 Ordinary Shares were withheld at $80.00 per share to cover taxes. Following this withholding, he directly holds 32,380 Ordinary Shares, which the footnotes state include 367 shares from dividend reinvestment and 191 shares acquired under Medtronic's Employee Stock Ownership Plan. This event reflects compensation and tax mechanics rather than an open-market stock sale.
Medtronic plc Chief Accounting Officer Denise L. Blomquist reported routine equity compensation activity. On April 27, 2026, she acquired 1,508 Ordinary Shares at $0.00 per share as a grant of restricted stock units that vest in three annual installments beginning one year from the grant date.
On April 28, 2026, 318 Ordinary Shares were disposed of at $81.90 per share, representing shares withheld to pay taxes upon vesting of previously granted restricted stock units, rather than an open-market sale. After these transactions, she directly owned 13,262 Ordinary Shares, including 106 shares acquired through dividend reinvestment since her last report.
Medtronic plc director Kendall J. Powell reported routine equity compensation activity. On April 27, 2026, he received a grant of 2,111 ordinary shares in the form of restricted stock units, which vest on the one-year anniversary of the award date. When previously granted restricted stock units vested, 207 shares of Medtronic ordinary shares were withheld at $81.90 per share to cover tax obligations rather than sold on the open market. After these transactions, Powell directly holds 51,380 ordinary shares, including 854 shares acquired through dividend reinvestment since his last report.
Medtronic plc director Elizabeth G. Nabel reported routine equity compensation activity in company ordinary shares. She received an award of 2,111 restricted stock units, which vest on the one-year anniversary of the award date. The filing also reports 207 shares withheld to cover taxes upon the vesting of previously granted restricted stock units, a non‑market, tax-withholding disposition rather than an open-market sale. Following these transactions, she directly holds 19,584 ordinary shares, including 65 shares acquired through dividend reinvestment since her last report.
Medtronic plc director Kevin E. Lofton reported routine equity compensation activity involving Ordinary Shares. On April 27, 2026, he acquired 2,111 shares at $0.00 per share as a grant of restricted stock units that vest on the one-year anniversary of the award date.
On April 28, 2026, 207 shares were withheld at $81.90 per share to cover taxes upon vesting of previously reported restricted stock units, a tax-withholding disposition rather than an open-market sale. Following these transactions, he directly holds 10,140 Ordinary Shares, which include 65 shares acquired through dividend reinvestment since his last report.
Medtronic plc director Lewis Gregory P reported routine equity compensation activity. On April 27, 2026, he acquired 2,111 Ordinary Shares through a grant of restricted stock units that vest on the one-year anniversary of the award date. The position also now includes 65 shares acquired through dividend reinvestment since his last report. On April 28, 2026, 207 shares were withheld at $81.90 per share to cover taxes upon the vesting of previously granted restricted stock units, a non-market disposition. After these transactions, he directly holds 5,754 Ordinary Shares.